This funding opportunity announcement (FOA) provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.
Companion FOAs:
PAR-21-123 , R61/ R33 Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II
PAR-21-124 , R61/ R33 Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II
Deadlines:
- Application Due Dates: June 17, 2021; Oct 19, 2021; Feb 22, 2022; June 21, 2022; Oct 18, 2022; Feb 21, 2023; June 20, 2023; Oct 20, 2023; Feb 20, 2024; June 20, 2024
PAR-21-122 Expiration Date New Date June 21, 2024 per issuance of NOT-NS-23-095. (Original Expiration Date: February 21, 2024)